Several smaller studies have targeted the IL-6 receptor and shown favorable effects on biomarkers and some indices of myocardial salvage, notably in the ASSAIL-MI (ASSessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction) study (4, 5). This evidence concerns the gene IL6 and myocardial infarction.